175 related articles for article (PubMed ID: 2809276)
1. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
von Wussow P; Jakschies D; Freund M; Deicher H
J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
[TBL] [Abstract][Full Text] [Related]
2. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
Dianzani F; Antonelli G; Amicucci P; Cefaro A; Pintus C
J Interferon Res; 1989 Sep; 9 Suppl 1():S33-6. PubMed ID: 2681442
[TBL] [Abstract][Full Text] [Related]
4. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
5. Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
Freund M; von Wussow P; Knüver-Hopf J; Mohr H; Pohl U; Exeriede G; Link H; Wilke HJ; Poliwoda H
Blut; 1988 Nov; 57(5):311-5. PubMed ID: 3196882
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferon-alpha.
Russo D; Candoni A; Zuffa E; Minisini R; Silvestri F; Fanin R; Zaja F; Martinelli G; Tura S; Botta G; Baccarani M
Br J Haematol; 1996 Aug; 94(2):300-5. PubMed ID: 8759890
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
[TBL] [Abstract][Full Text] [Related]
8. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha neutralizing antibodies in HIV and chronic HCV patients treated with natural-source human leukocyte-derived interferon-alpha n3.
Zhao XX; Hua J; Smith T; Ferencz-Biro K; Liao MJ; Rashidbaigi A
Hum Antibodies; 1997; 8(3):129-36. PubMed ID: 9322083
[TBL] [Abstract][Full Text] [Related]
10. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2.
Nolte KU; Günther G; von Wussow P
Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261
[TBL] [Abstract][Full Text] [Related]
11. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
Spiegel RJ; Jacobs SL; Treuhaft MW
J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
[TBL] [Abstract][Full Text] [Related]
12. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.
Michallet M; Maloisel F; Delain M; Hellmann A; Rosas A; Silver RT; Tendler C;
Leukemia; 2004 Feb; 18(2):309-15. PubMed ID: 14671645
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia.
Anger B; Porzsolt F; Leichtle R; Heinze B; Bartram C; Heimpel H
Blut; 1989 Jun; 58(6):275-8. PubMed ID: 2736308
[TBL] [Abstract][Full Text] [Related]
14. Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia.
Von Wussow P; Hehlmann R; Hochhaus T; Jakschies D; Nolte KU; Prümmer O; Ansari H; Hasford J; Heimpel H; Deicher H
J Interferon Res; 1994 Aug; 14(4):217-9. PubMed ID: 7822880
[No Abstract] [Full Text] [Related]
15. Therapy-induced antibodies against the antiviral and antiproliferative effects of interferons in patients with chronic hepatitis C virus infection.
Bálint E; Bakay M; Onody K; Farkas F; Horváth G; Tolvaj G; Dávid K; Horányi M; Béládi I
Acta Microbiol Immunol Hung; 2004; 51(3):359-69. PubMed ID: 15571075
[TBL] [Abstract][Full Text] [Related]
16. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
Bekisz JB; zur Nedden DL; Enterline JC; Zoon KC
J Interferon Res; 1989 Sep; 9 Suppl 1():S1-7. PubMed ID: 2809275
[TBL] [Abstract][Full Text] [Related]
17. [Autoimmune phenomena during interferon-alpha therapy for hematopoietic disorders].
Iguchi T; Nishimaki J; Kawakubo K; Shimamoto T; Iwase O; Suzuki A; Kuriyama Y; Ito Y; Tauchi T; Yaguchi M; Miyazawa K; Kimura Y; Ohyashiki K
Gan To Kagaku Ryoho; 2003 Nov; 30(12):1911-6. PubMed ID: 14650958
[TBL] [Abstract][Full Text] [Related]
18. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.
Ross C; Svenson M; Hansen MB; Vejlsgaard GL; Bendtzen K
J Clin Invest; 1995 May; 95(5):1974-8. PubMed ID: 7738163
[TBL] [Abstract][Full Text] [Related]
19. Emergence and decay of the human Mx homolog in cancer patients during and after interferon-alpha therapy.
Jakschies D; Hochkeppel H; Horisberger M; Deicher H; von Wussow P
J Biol Response Mod; 1990 Jun; 9(3):305-12. PubMed ID: 2380745
[TBL] [Abstract][Full Text] [Related]
20. [Effects of recombinant human alpha-2b and gamma interferons on bone marrow megakaryocyte progenitors (CFU-Meg) from patients with chronic myelocytic leukemia].
Tanabe Y; Dan K; Kuriya S; Nomura T
Rinsho Ketsueki; 1989 Oct; 30(10):1800-5. PubMed ID: 2512397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]